Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1α,25-dihydroxycholecalciferol, All-Trans retinoic acid, 9-Cis retinoic acid, and phenylacetate

Prostate

Volumn 28, Issue 3, 1996, Pages 182-194

  Esquenet, Murielle ^a   Swinnen, Johannes V ^a   Heyns, Walter ^a   Verhoeven, Guido ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Differentiation therapy; Prostate cancer; Prostate specific antigen; Retinoids; Vitamin D

Indexed keywords

ALITRETINOIN; ANDROGEN; ANDROGEN RECEPTOR; CALCITRIOL; CHARCOAL; DEXTRAN; METRIBOLONE; MIBOLERONE; PHENYLACETIC ACID; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID; THYMIDINE; TRITIUM;

ARTICLE; CARCINOMA CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FETAL CALF SERUM; GROWTH INHIBITION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANDROGENS; ANTIMETABOLITES, ANTINEOPLASTIC; CALCITRIOL; CELL DIFFERENTIATION; CELL DIVISION; HUMANS; MALE; PHENYLACETATES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; THYMIDINE; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0029966081     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199603)28:3<182::AID-PROS5>3.0.CO;2-H     Document Type: Article

References (51)

1. Carter HB, Coffey DS: The prostate: An increasing medical problem. Prostate 16:39-48, 1990.
2. Garnick MB: Prostate cancer: Screening, diagnosis, and management. Ann Intern Med 118:804-818, 1993.
3. 3. Cancer Res 52:515-520, 1992.
4. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960, 1993.
5. 3 on primary cultures of human prostatic cells. Cancer Res 54:805-810, 1994.
6. Peehl DM, Wong ST, Stamey TA: Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate 23:69-78, 1993.
7. Fong C-J, Sutkowski DM, Braun EJ, Bauer KD, Sherwood ER, Lee C, Kozlowski JM: Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J Urol 149:1190-1194, 1993.
8. Stearns ME, Wang M, Fudge K: Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity. Cancer Res 53:3073-3077, 1993.
9. Dahiya R, Boyle B, Park H-D, Kurhanewicz J, Macdonald JM, Narayan P: 13-cis-retinoic acid-mediated growth inhibition of DU-145 human prostate cancer cells. Biochem Mol Biol Int 32:1-12, 1994.
10. Samid D, Shack S, Myers CE: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 91:2288-2295, 1993.
11. Hanchette CL, Schwartz GG: Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer 70:2861-2869, 1992.
12. Reichman ME, Hayes RB, Ziegler RG, Schatzkin A, Taylor PR, Kahle LL, Fraumeni JF: Serum vitamin A and subsequent development of prostate cancer in the first national health and nutrition examination survey epidemiologic follow-up study. Cancer Res 50:2311-2315, 1990.
13. Willett WC, Hunter DJ: Vitamin A and cancers of the breast, large bowel, and prostate: Epidemiologic evidence. Nutr Rev 52:S53-S59, 1994.
14. Wilding G, Valverius E, Knabbe C, Gelmann EP: Role of transforming growth factor-α in human prostate cancer cell growth. Prostate 15:1-12, 1989.
15. Schuurmans ALG, Bolt J, Veldscholte J, Mulder E: Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J Steroid Biochem Mol Biol 40:193-197, 1991.
16. Knabbe C, Kellner U, Schmahl M, Voight K-D: Growth factors in human prostate cancer cells: Implications for an improved treatment of prostate cancer. J Steroid Biochem Mol Biol 40:185-192, 1991.
17. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C: Autonomous growth of androgen-independent human prostatic carcinoma cells: Role of transforming growth factor α. Cancer Res 51:2780-2785, 1991.
18. Nakamoto T, Chang C, Li A, Chodak GW: Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 52:571-577, 1992.
19. MacDonald A, Habib FK: Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 65: 177-182, 1992.
20. Berns EMJJ, de Boer W, Mulder E: Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 9:247-259, 1986.
21. Schuurmans ALG, Bolt J, Mulder E: Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 12:55-63, 1988.
22. Kokontis J, Takakura K, Hay N, Liao S: Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54:1566-1573, 1994.
23. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818, 1983.
24. Schulz P, Bauer HW, Fittler F: Steroid hormone regulation of prostatic acid phosphatase expression in cultured human prostatic carcinoma cells. Biol Chem Hoppe Seyler 366:1033-1039, 1985.
25. Henttu P, Vihko P: Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line. J Steroid Biochem Mol Biol 41:349-360, 1992.
26. Montgomery BT, Young CY-F, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ: Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 21:63-73, 1992.
27. Lin M-F, Garcia-Arenas R, Chao Y-C, Lai MMC, Patel PC, Xia X-Z: Regulation of prostatic acid phosphatase expression and secretion by androgen in LNCaP human prostate carcinoma cells. Arch Biochem Biophys 300:384-390, 1993.
28. Wilding G, Chen M, Gelmann EP: Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14:103-115, 1989.
29. Olea N, Sakabe K, Soto AM, Sonnenschein C: The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 126:1457-1463, 1990.
30. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GGJM, Jenster G, Trapman J, Brinkmann AO, Mulder E: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41:665-669, 1992.
31. Veldscholte J, Berrevoets CA, Mulder E: Studies on the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 49:341-346, 1994.
32. Giguère V: Retinoic acid receptors and cellular retinoid binding proteins: Complex interplay in retinoid signaling. Endocr Rev 15:61-79, 1994.
33. Green B, Leake RE: "Steroid Hormones: A Practical Approach." Oxford: IRL Press, Oxford University Press, 1987.
34. Labarca C, Paigen K: A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102:344-352, 1980.
35. Verhoeven G, Cailleau J: Testicular peritubular cells secrete a protein under androgen control that inhibits induction of aromatase activity in sertoli cells. Endocrinology 123:2100-2110, 1988.
36. Schulz P, Wolf D, Arbusow V, Bojar H, Klobeck H-G, Fittler F: The synthetic androgen mibolerone induces transcient suppression of the transformed phenotype in an androgen responsive human prostatic carcinoma cell line. Andrologia 22(Suppl 1P):56-65, 1990.
37. Langeler EG, van Uffelen CJC, Blankenstein MA, van Steenbrugge GJ, Mulder E: Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate 23:213-223, 1993.
38. Kirschenbaum A, Ren M, Levine AC: Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line. Steroids 58: 439-444, 1993.
39. Swinnen JV, Esquenet M, Heyns W, Rombauts W, Verhoeven G: Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP. Mol Cell Endocrinol Mol. Cell. Endocrinol. 104:153-162, 1994.
40. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240:889-895, 1988.
41. O'Malley B: The steroid receptor superfamily: More excitement predicted for the future. Mol Endocrinol 4:363-369, 1990.
42. Yu VC, Deisert C, Andersen B, Holloway JM, Devary OV, Näär AM, Kim SY, Boutin J-M, Glass CK, Rosenfelk MG: RXRβ: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell 67:1251-1266, 1991.
43. Zhang X-K, Hoffmann B, Tran PB-V, Graupner G, Pfahl M: Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 355:441-446, 1992.
44. Leid M, Kastner P, Lyons R, Nakshatri H, Saunders M, Zacharewski T, Chen J-Y, Staub A, Garnier J-M, Mader S, Chambon P: Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell 68:377-395, 1992.
45. Bugge TH, Pohl J, Lonnoy O, Stunnenberg HG: RXRα, a promiscuous partner of retinoic acid and thyroid hormone receptors. EMBO J 11:1409-1418, 1992.
46. Marks MS, Hallenbeck PL, Nagata T, Segars JH, Appella E, Nikodem VM, Ozato K: H-2RIIBP (RXRβ) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes. EMBO J 11:1419-1435, 1992.
47. 3 signaling. Nature 355:446-449, 1992.
48. Rosen ED, O'Donnell AL, Koenig RJ: Ligand-dependent synergy of thyroid hormone and retinoid X receptors. J Biol Chem 267:22010-22013, 1992.
49. Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, Hunziker W: Two nuclear signalling pathways for vitamin D. Nature 361:657-660, 1993.
50. Mangelsdorf DJ: Vitamin A receptors. Nutr Rev 52:S32-S44, 1994.
51. Eppinger TM, Buck J, Hämmerling U: Growth control or terminal differentiation: Endogenous production and differential activities of vitamin A metabolites in HL-60 cells. J Exp Med 178:1995-2005, 1993.